Short answer
Dyne Therapeutics, Inc. (DYN) filed its Q2 2026 10-Q quarterly report on Jul 29, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$179M
- −61.1% YoY · −47.7% QoQ
- EPS (diluted)
- −$1.08
- −11.3% YoY · −47.9% QoQ
Source: XBRL data from the Dyne Therapeutics, Inc. (DYN) Q2 2026 10-Q on SEC EDGAR. USD.
Dyne Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales generated
- Net loss $178.6M vs $110.9M YoY; operating loss $181.7M vs $115.8M
- R&D expense $152.2M vs $99.2M; z-rostudirsen highest program at $52.3M
- July offering generated approximately $405.0M net proceeds; funding expected into Q2 2028
- Potential z-rostudirsen U.S. launch Q1 2027; tariffs may increase supply-chain costs and delay development
Risk Factors
- Newly triggered financing risk: July 2026 offering added approximately $405.0 million net proceeds but may deplete sooner than expected
- Most material update: Hercules Loan Agreement amended in June 2026, adding third-tranche borrowing and new covenant exposure
- Debt compliance risk: Minimum Cash Covenant begins July 1, 2027 at 40% of outstanding obligations when market capitalization is below $1.65 billion
- Regulatory risk: FDA clinical holds or additional preclinical requests could delay trials, as occurred with z-rostudirsen before July 2022 clearance
- Near-term development risk: Product candidates remain preclinical or clinical, with commercialization not expected until at least 2027, if ever
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dyne Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.